Context Therapeutics Inc. (CNTX) Stock Overview
Explore Context Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Context Therapeutics Inc. (CNTX)
Key Financials
Key Financials
Market Cap
33.8M
P/E Ratio
-0.76
EPS (TTM)
$-0.48
ROE
-0.82%
CNTX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Context Therapeutics Inc. (NASDAQ: CNTX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Context Therapeutics Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CNTX on the NASDAQ shows an RSI of 37.19, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $1.22 for the NASDAQ listing.
Key metrics behind Context Therapeutics Inc.'s NASDAQ-traded stock include a P/E ratio of -0.76 and a market capitalization of 33.8M. Combined with our AI analysis, these give both institutional and retail investors a clear view of CNTX on the NASDAQ.